Member Info for flyingmachine

Late Tuesday afternoon.

The US Covid test market is getting bigger, and bigger, and bigger......and Genedrive are up to the challenge offering Genedrive's top tier PCR test. Not concerned about the competition, DB looks confident in his sunglasses and cheeky smile ;-)
Roll on FDA approval, gotta be close now.
https://twitter.com/Blowster85/status/1278033432577179652/photo/1

Endion, Abingdon are working on their own antigen LFT test in partnership with Imperial College London. So there is some dependence on the result of their own development and whether they would choose to manufacture a potential competitor product.

The likes of Omega Diagnostics could manufacture for Avacta. They are already building capacity to make up to 1m Covid tests/week, both lab and LFTs.

Magsy, totally agree with your confidence.

Magsy, list 3 confident statements you can make about GDR, your one and only Covid investment?

Wonderful! That wasn't hard was it!

Magsy, tell us why you stay invested in GDR?

DB sent a validation submission for the GDR POC test, a day or so ago, back to the DHSC 'Desktop PCR for Point of Care testing' challenge programme. They responded with ........

"Thank you for your submission David, can you send the full report and data for the validation trial carried out as Bev requested. With this we hope to bring the solution back to our reviewers"

The details for validation were requested by DHSC from GDR a couple of months back, so looks like GDR have been working hard on development and validation since then, but also had likely been waiting for MHRA publication of TPP for Covid-19 POC tests.

This suggests GDR POC development team have reached a key validation milestone - the TPPs for POC testing were only published by the MHRA on 26th June. I expect that DB would not be responding with development validation results if these MHRA requirements were not being met.

https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/895745/TPP_Point_of_Care_SARS-CoV-2_Detection_Tests.pdf

The way I see these two sets of parameters, the 'acceptable' level are geared towards mass screening antigen rapid tests such as the one Avacta are developing. The 'desired' set of parameters are most likely the target for professionally instrumented POC use cases, which replicate the level of accuracy of PCR molecular or LAMP type testing at POC.

Avacta just need to shoot as high as possible in the 'acceptable' space.

Desired sensitivity - greater than 97%
Desired specificity - greater than 99%

Acceptable sensitivity - greater than 80%
Acceptable specificity - greater than 95%

https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/895745/TPP_Point_of_Care_SARS-CoV-2_Detection_Tests.pdf

Not sure it would be Abingdon. Abingdon are working on their own rapid antigen test according to their recent hire, Prof Mike Holmes, which could be the same test related to the POC antigen test they are developing in partnering with Imperial College London.

PL, I see you've had an entertaining time over the other board recently - trying to inject a balance of risk is not a thankful task on some boards. Agree that there is room for both PCR tests and POC tests as they complement each other in the Covid testing landscape. Hence GDR is also developing their own POC test to run on the GDR platform.

Even in current markets the need for Covid-19 PCR tests is getting even bigger, not smaller, to the extent that Roche chairman has recently stated their company has maxed out on PCR test production and cannot produce enough to meet demand. No problem, GDR can churn out 10000/hour and apparently can expand this manufacturing rate per hour if needed.

Next week should hopefully the week we still start to see the news flow we have all been waiting patiently for.

hants, yes, short or longer term, a potential opportunity.

PL and RD, regarding ODX placement and potential. The placement was at 40p and open to existing retail investors, so SP is still around 25% above placement price. Placement funding to be used scale up test manufacturing of both lab and LFT Covid tests from 100k/week to 1 million per week. ODX have agreements to manufacture 5 kinds of tests currently - 2 lab tests from Mologic (antigen and antibody), 2 LFT tests from Mologic (antigen and antibody) an 1 LFT test for RTC antibody test. They can proportion and scale their manufacturing according to which tests are most wanted. To do this investment in manufacture they are stopping development of other non-Covid tests they were working on and willing to lose £8m in letting that non-Covid development go - just goes to show how much they expect to benefit from manufacturing these 5 Covid tests. May even be an opportunity to manufacture Avacta tests when it becomes available!

nm

Pigster, yes I understand that, but was clarifying the 'ambition' statement in PLs post, which I did not believe to be fully correct.

PL75, I think Alistair stated ambitions for achieving minimum 90% sensitivity and 95% specificity in his recent video. He never stated they will get 95% sensitivity.

...specifically listen between 23m 40 secs in to 26min. You get your answer.

Report from involved sources about ICMR testing progress in India....

A couple of slight hiccups in the ICMR testing......like the Indian Govt testing machine breaking etc. But the team has been on hand to counter every issue as it has come up, so testing is progressing right now and expecting outcome data next week